Abstract 132P
Background
Oncogenic mutation p53(Y220C) is the ninth most common mutation of the p53 protein. Mutation Y220C creates an expanded surface pocket in the DNA-binding domain of p53, due to which the protein is rapidly denatured under physiological conditions. This also negatively affects the effectiveness of p53-dependent signaling and leads to tumor development. In this work, new indazole derivatives were investigated as modulators of mutant p53 activity. We found that the compounds studied were able to initiate an anti-tumor cellular response by activating mutant p53(Y220C).
Methods
Immunocytochemical analysis (ICC) was performed to test the hypothesis that the mutant protein p53(Y220C) can restore its native-like conformation and get reactivated upon interaction with the compounds. The degree of p53 activation was evaluated, and the protein localization in HUH7 p53(Y220C) human hepatocarcinoma cells was determined upon treatment with indazole derivatives.
Results
During the immunocytochemical analysis, images obtained were analyzed using the ImageJ software, and the values of p53 signal intensity were calculated. We found that in comparison with control untreated cells, in samples treated with indazole derivatives increased in levels of p53 were observed mainly in the nucleus, which indicates its activation.
Conclusions
The results of the immunocytochemical analysis demonstrated that indazole derivatives specifically activate mutant p53(Y220C) protein. The compounds represent a promising basis for the development of selective activators not only for Y220C, but also for other mutant forms of p53. The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract